Proqr Therapeutics N.V. (PRQR) 19.46 $PRQR Nasdaq stocks

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Tilray Brands Delivers Record Q1 Revenue Tilray Brands (NASDAQ: TLRY) has announced an impressive net revenue of $200 million for its first fiscal quarter, showcasing a remarkable 13% increase from the previous year. The significant boost can largely be attributed to the exponential growth within its beverage sector, including both traditional craft beers and innovative...

Exor N.V. Reports Robust Year-End Performance Exor N.V. has once again demonstrated significant growth and strategic financial management through its latest annual results. The company reported an impressive 9% growth in Net Asset Value (NAV) per share for the fiscal year, reaching €38.2 billion by year-end. This financial achievement reflects Exor's robust operational...

Integral Ad Science Holding Corp. Faces Securities Fraud Allegations Levi & Korsinsky, LLP is reaching out to the investors of Integral Ad Science Holding Corp. (NASDAQ: IAS), as there is an ongoing class action securities lawsuit that could allow affected investors to recover losses. Understanding the Class Action Details This class action lawsuit aims to represent those...

Expanding Horizons: Powered Research's New Oncology Services For over a decade, Powered Research has earned its reputation as a premier preclinical contract research organization (CRO), particularly in the field of ophthalmology. Today, the company takes a monumental step forward by launching an extensive suite of oncology preclinical services. This new direction is set...

Jim Cramer Sees Potential in Dominion Energy In a recent episode of CNBC's programming, well-known financial commentator Jim Cramer highlighted Dominion Energy, Inc. (D) as a promising buy. He stated, "We need cheap power," which underscores the increasing demand for affordable energy solutions in today's unpredictable market landscape. Analyst Ratings for Dominion Energy...